


About

PIONEER (NCT03731260) is a randomized, double-blind, placebo-controlled phase 2 study of avapritinib* with best supportive care in people with indolent SM (ISM).

PIONEER study design¹

Phase 2, three-part, placebo-controlled trial



RP2D, recommended phase 2 dose.

Key study eligibility¹

- At least 18 years of age
- Centrally confirmed ISM per WHO diagnostic criteria
- Moderate to severe ISM based on ISM-SAF patient-reported outcome tool
- Must not have a restriction based on prior therapy

* Avapritinib is an investigational compound being studied in advanced systemic mastocytosis. It is not approved in this indication by the U.S. Food & Drug Administration or any other regulatory body.

ISM, indolent SM; ISM-SAF, Indolent Systemic Mastocytosis Symptom Assessment Form; WHO, World Health Organization.

This trial will be enrolling patients at clinical sites globally.

For more information, please visit www.pioneertrial.com or e-mail us at medinfo@blueprintmedicines.com.

Reference: 1. <https://clinicaltrials.gov/ct2/show/NCT03731260>. Accessed October 13, 2020.

10/2020 US-BP-MED-AVA-20029.1

Blueprint Medicines and associated logo are trademarks of Blueprint Medicines Corporation.

©2020 Blueprint Medicines Corporation